

5 key facts about cholangiocarcinoma



Although rare, the incidence of cholangiocarcinoma, in particular intrahepatic cholangiocarcinoma, is generally **increasing worldwide**¹



~70% of patients with cholangiocarcinoma are diagnosed with advanced disease, which compromises **therapeutic options** and leads to a **poor prognosis**²

A **multidisciplinary team approach** enables a more comprehensive understanding of disease biology and **collaboration options** for patients with cholangiocarcinoma³



Biopsy technique should account for planned **molecular profiling** as well as **diagnostic needs**⁴

~50% of patients with cholangiocarcinoma have at least one potentially **actionable genomic alteration**, supporting the rationale for **molecular profiling at diagnosis**⁵



If you would like to request further medical information, please visit: www.incyteglobalmedicalinformation.com

REFERENCES:

1. Bañales JM, et al. *Nat Rev Gastroenterol Hepatol*. 2016;13:261–80;
2. Bañales JM, et al. *Nat Rev Gastroenterol Hepatol*. 2020;17:557–88;
3. Patel T. *Nat Rev Gastroenterol Hepatol*. 2011;8:189–200;
4. Cree IA, et al. *J Clin Pathol*. 2014;67:923–31;
5. Lowery MA, et al. *Clin Cancer Res*. 2018;24:4154–61.

UK/PEMA/NP/21/0005; EU/PEMA/NP/21/0002;
NL/PEMA/NP/21/0007; ES/PEMA/NP/21/0003;
DK/PEMA/NP/21/0011; CH/PEMA/NP/21/0001;
BE/PEMA/NP/21/0011

Date of preparation: April 2021.

© 2022, Incyte Biosciences International Sàrl. All rights reserved.
The Incyte logo is a registered trademark of Incyte.